Company News

Share this article:

Sanofi-Aventis will acquire California-based BiPar Sciences for up to $500 million. BiPar Sciences is a pharma focused on a novel cancer treatment, known as BSI-201. The acquisition is the third this month for Sanofi – the company purchased Medley, a Brazillian generics manufacturer, and Laboratorious Kendrick, a Mexican generic company.

 

Johnson & Johnson announced that it will shift its wellness and disease-prevention business under the consumer business umbrella. J&J had initially planned to develop a separate wellness and disease-prevention business, with the acquisition of Michigan-based HealthMedia, according to a Wall Street Journal report.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.